

TECHNICAL DATA SHEET

CyFlow™ DR3 PE Anti-Hu; Clone JD3



AR915896

For Research Use Only.

Not for use in diagnostic or therapeutic procedures.

Specifications

Antigen	DR3		
Alternative Names	TRAM		
Clone	JD3		
Clonality	monoclonal		
Format	PE		
Host / Isotype	Mouse / IgG1		
Species Reactivity	Human		
Negative Species Reactivity	_		
Quantity	100 tests		
Immunogen	Human DR3-Ig fusion protein		

Specificity

The mouse monoclonal antibody JD3 recognizes DR3 antigen, a transmembrane protein of TNFR superfamily expressed mainly in lymphocyte-enriched tissues.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: <u>info@sysmex-partec.com</u>

Rev 1.0 Date: 2016-05-26 EN CyFlow™ DR3 PE



Application

The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10 μ l reagent / 100 μ l of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Other usages may be determined from the scientific literature.

Storage Buffer

The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.

Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

Background Information

DR3 (APO-3, TRAMP, TNFRSF12) is a death domain-containing receptor of TNFR family, which is expressed preferentially in peripheral blood leukocytes and in the lymphocyte-enriched tissues. Its expression has been shown to be especially up-regulated in activated T cells. DR3 participates e.g. in the removal of self-reactive T cells in the thymus. The ligand for DR3 is TL1A (TNF-like ligand 1A), which is expressed in a variety of cell types (induced by inflammatory stimuli), and can also be released as a soluble factor. The TL1A/DR3 axis has been shown to costimulate T cells to produce a wide variety of cytokines and leads to T cell differentiation towards Th1 and Th17 types.

References

- Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K, Yagita H: Multiple pathways of TWEAK-induced cell death. J Immunol. 2002 Jan 15; 168(2):734-43.
 PMID: 11777967 >
- Jones GW, Stumhofer JS, Foster T, Twohig JP, Hertzog P, Topley N, Williams AS, Hunter CA, Jenkins BJ, Wang EC, Jones SA: Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J. 2011 Jan; 25(1):409-19.
 < PMID: 20826539 >
- Yi B, Zhang M, Schwartz-Albiez R, Cao Y: Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells. Int J Oncol. 2011 Jun; 38(6):1565-73. < PMID: 21455576 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Rev 1.0 Date: 2016-05-26 EN CyFlow™ DR3 PE



	lls. PLoS One. 2	,					
The Safety Data Sheet for this product is available at www.sysmex-partec.com/services.							

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Rev 1.0 Date: 2016-05-26 EN CyFlow™ DR3 PE